Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director | June 12, 2026 | June 15, 2026 |
| TREVENA INCTRVN · Entity 85383 | Director | June 13, 2024 | June 14, 2024 |
| vTv Therapeutics Inc.VTVT · Entity 6614 | Director | June 26, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sagimet Biosciences Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2036-06-11 | Direct | 39,567 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 39,567 · Balance 39,567 F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.
TREVENA INC
Report date June 13, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2034-06-13 | Direct | 13,700 |
Reported balance
After 2024-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-13 · Grant · Acquired 13,700 · Balance 13,700 F1: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date.
vTv Therapeutics Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.08 · Expires 2036-06-26 | Direct | 16,860 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 6,000 · Balance 16,860 F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMAG PHARMACEUTICALS, INC.
Report date November 16, 2020 · Filed November 17, 2020
Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 18,949 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 1,200 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 17,326 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 21,289 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.
F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Barinthus Biotherapeutics plc.
Report date September 09, 2026 · Filed September 09, 2026
Section 16 reporting ended · disclosed 2026-09-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-09 · Disposition to issuer · Disposed 3,000 · Balance 0 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F3: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-05-01 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-09 · Disposition to issuer · Disposed 34,328 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27 · Expires 2032-06-15 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-09 · Disposition to issuer · Disposed 18,604 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2033-05-11 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-09 · Disposition to issuer · Disposed 19,197 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2034-05-10 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-09 · Disposition to issuer · Disposed 19,516 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-09 · Disposition to issuer · Disposed 20,174 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco.
F3: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock").
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 9, 2026 20:20 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerShare Option (Right to Buy) · Derivative | 20,174 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-26-106341 · tm2625057-6_4seq1.xml · derivative · entry 6 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,174 shares Expires 2035-06-10 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 20:20 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerShare Option (Right to Buy) · Derivative | 19,516 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001104659-26-106341 · tm2625057-6_4seq1.xml · derivative · entry 5 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 19,516 shares Expires 2034-05-10 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 20:20 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerShare Option (Right to Buy) · Derivative | 19,197 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001104659-26-106341 · tm2625057-6_4seq1.xml · derivative · entry 4 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 19,197 shares Expires 2033-05-11 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 20:20 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerShare Option (Right to Buy) · Derivative | 18,604 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001104659-26-106341 · tm2625057-6_4seq1.xml · derivative · entry 3 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 18,604 shares Expires 2032-06-15 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 20:20 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerShare Option (Right to Buy) · Derivative | 34,328 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-26-106341 · tm2625057-6_4seq1.xml · derivative · entry 2 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 34,328 shares Expires 2031-05-01 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 20:20 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerOrdinary Shares | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-106341 · tm2625057-6_4seq1.xml · nonDerivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F3 · shares: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). F3 · price: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 20:08 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 6,000 | $35.08 Strike: $35.08 | $210,480.00 |
DisclosureSEC source: 0001627680-26-000006 · wk-form4_1782763711.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,860 Underlying: Class A Common Stock · 6,000 shares Expires 2036-06-26 F1 · derivative.exercise_date: The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:19 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 39,567 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001104659-26-074044 · tm2617570-1_4seq1.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,567 Underlying: Series A Common Stock · 39,567 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:15 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 20,174 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001828185-25-000043 · wk-form4_1749676523.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,174 Underlying: Ordinary Shares · 20,174 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the earlier of (i) June 10, 2026 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:26 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 4,000 | $16.59 Strike: $16.59 | $66,360.00 |
DisclosureSEC source: 0001641489-25-000042 · wk-form4_1749759962.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,860 Underlying: Class A Common Stock · 4,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option vests on the earlier of June 10, 2026, and the date of the 2026 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 21:41 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 27,268 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001104659-25-058224 · tm2517621-5_4seq1.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,268 Underlying: Series A Common Stock · 27,268 shares Expires 2035-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:08 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 113,895 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001104659-24-085818 · tm2420761-3_4seq1.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,895 Underlying: Series A Common Stock · 113,895 shares Expires 2034-07-31 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over thirty-six (36) equal monthly installments following August 1, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:37 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 860 | $17.22 Strike: $17.22 | $14,809.20 |
DisclosureSEC source: 0001641489-24-000047 · wk-form4_1719520629.xml · derivative · entry 2 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,860 Underlying: Class A Common Stock · 860 shares Expires 2034-06-25 F2 · derivative.exercise_date: The options will vest in full on the one-year anniversary of the date of grant Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:37 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 2,250 | $17.22 Strike: $17.22 | $38,745.00 |
DisclosureSEC source: 0001641489-24-000047 · wk-form4_1719520629.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Class A Common Stock · 2,250 shares Expires 2034-06-25 F1 · derivative.exercise_date: The options will vest monthly over the three year period following the date of grant. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:39 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 13,700 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001062993-24-012663 · form4.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,700 Underlying: Common Stock · 13,700 shares Expires 2034-06-13 F1 · derivative.exercise_date: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:19 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 19,516 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001828185-24-000054 · wk-form4_1715717940.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,516 Underlying: Ordinary Shares · 19,516 shares Expires 2034-05-10 F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the earlier of (i) May 10, 2025 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 13, 2024 Filed Jun 13, 2024 20:37 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 3,750 | $16.04 Strike: $16.04 | $60,150.00 |
DisclosureSEC source: 0001641489-24-000038 · wk-form4_1718311014.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Class A Common Stock · 3,750 shares Expires 2034-03-13 F1 · derivative.exercise_date: The option vests in monthly installments over the three-year period beginning March 13, 2024. The option was granted upon Dr. Phillips' appointment to the Board but was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:37 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 13,700 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001062993-23-013834 · form4.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,700 Underlying: Common Stock · 13,700 shares Expires 2033-06-15 F1 · derivative.exercise_date: The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 11, 2023 Filed May 12, 2023 20:07 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 19,197 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001104659-23-059726 · tm2315647-4_4seq1.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,197 Underlying: Ordinary Shares · 19,197 shares Expires 2033-05-11 F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the earlier of (i) May 11, 2024 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 15, 2022 Filed Feb 10, 2023 21:39 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 18,604 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001104659-23-018607 · tm236344-4_5seq1.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,604 Underlying: Ordinary Shares · 18,604 shares Expires 2032-06-15 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on June 15, 2023, with the remainder vesting in 24 equal monthly installments thereafter. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:26 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001062993-22-014807 · form4.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 21:00 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 68,577 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001429560-21-000004 · edgar.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,577 Underlying: Common Stock · 68,577 shares Expires 2031-05-28 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:25 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | PurchaseOrdinary Shares | 3,000 | $17.00 | $51,000.00 |
DisclosureSEC source: 0001104659-21-062424 · tm2115262-2_4seq1.xml · nonDerivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 5, 2021 00:26 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 34,328 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061227 · tm2114558-23_4seq1.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,328 Underlying: Ordinary Shares · 34,328 shares Expires 2031-04-29 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:47 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126331 · a4.xml · derivative · entry 5 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,289 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:47 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126331 · a4.xml · derivative · entry 4 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,326 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:47 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126331 · a4.xml · derivative · entry 3 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,200 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:47 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126331 · a4.xml · derivative · entry 2 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:47 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerCommon Stock | 18,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126331 · a4.xml · nonDerivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 16:50 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 21,289 | Not disclosed Strike: $8.52 | Not disclosed |
DisclosureSEC source: 0000792977-20-000062 · wf-form4_159130382017867.xml · derivative · entry 2 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,289 Underlying: Common Stock · 21,289 shares Expires 2030-06-02 F2 · price: Not applicable. F3 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 16:50 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 10,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-20-000062 · wf-form4_159130382017867.xml · nonDerivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,949 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to theIssuer. F2 · price: Not applicable. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:27 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 64,103 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001209191-20-029786 · doc4.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,103 Underlying: Common Stock · 64,103 shares Expires 2030-05-13 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 16, 2019 Filed May 16, 2019 21:34 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001209191-19-030529 · doc4.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 16, 2019 Filed May 20, 2019 07:29 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 17,326 | Not disclosed Strike: $10.78 | Not disclosed |
DisclosureSEC source: 0000792977-19-000105 · wf-form4_155835176487341.xml · derivative · entry 2 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,326 Underlying: Common Stock · 17,326 shares Expires 2029-05-16 F2 · price: Not applicable. F3 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders. Read SEC document |
| May 16, 2019 Filed May 20, 2019 07:29 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 8,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-19-000105 · wf-form4_155835176487341.xml · nonDerivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,680 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2 · price: Not applicable. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 16:28 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 1,200 | Not disclosed Strike: $12.92 | Not disclosed |
DisclosureSEC source: 0000792977-19-000075 · wf-form4_155510087651744.xml · derivative · entry 3 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 1,200 shares Expires 2029-04-10 F2 · price: Not applicable. F4 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable on May 1, 2019. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 16:28 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $12.92 | Not disclosed |
DisclosureSEC source: 0000792977-19-000075 · wf-form4_155510087651744.xml · derivative · entry 2 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-04-10 F2 · price: Not applicable. F3 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twenty-four equal monthly installments over two years from the date of grant. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 16:28 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-19-000075 · wf-form4_155510087651744.xml · nonDerivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the "Plan") that will vest on May 1, 2019; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2 · price: Not applicable. Read SEC document |
| May 16, 2018 Filed May 17, 2018 21:10 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001209191-18-031038 · doc4.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
| May 17, 2017 Filed Jun 6, 2017 20:45 UTC | TREVENA INC TRVN · Entity 85383 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-17-038144 · doc4.xml · derivative · entry 1 Phillips Anne M. · CIK 0001627680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-17 F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.